Expanding roles of the hypoxia-response network in chronic kidney disease

Clinical and Experimental Nephrology

Volumn 20, Issue 6, 2016, Pages 835-844

  Tanaka, Tetsuhiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic kidney disease (CKD); Hypoxia; Hypoxia inducible factor (HIF); Prolyl hydroxylase (PHD)

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROLYL HYDROXYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; FIBROBLAST; GENETIC TRANSCRIPTION; GLOMERULUS; HEREDITY; HUMAN; HYPOXIA; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY TUBULE EPITHELIUM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; RENAL ANEMIA; RENAL PROTECTION; REVIEW; UREMIA; COMPLICATION; EPITHELIAL MESENCHYMAL TRANSITION; OXYGEN CONSUMPTION; PATHOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1; OXYGEN CONSUMPTION; PROLYL-HYDROXYLASE INHIBITORS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84957627506     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-016-1241-4     Document Type: Review

References (80)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305. doi:10.1056/NEJMoa041031.
2. Bohle A, Von Gise H, Mackensen-Haen S, Stark-Jakob B. The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli. Functional interpretation of morphologic findings. Klin Wochenschr. 1981;59(18):1043–51.
3. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13(3):806–16.
4. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl. 2000;75:S22–6.
5. Tanaka T, Miyata T, Inagi R, Kurokawa K, Adler S, Fujita T, et al. Hypoxia-induced apoptosis in cultured glomerular endothelial cells: involvement of mitochondrial pathways. Kidney Int. 2003;64(6):2020–32. doi:10.1046/j.1523-1755.2003.00301.x.
6. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, et al. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int. 2004;65(3):871–80. doi:10.1111/j.1523-1755.2004.00461.x.
7. Kawakami T, Mimura I, Shoji K, Tanaka T, Nangaku M. Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes (2011). Kidney Int Suppl. 2014;4(1):107–12. doi:10.1038/kisup.2014.20.
8. Matsumoto M, Tanaka T, Yamamoto T, Noiri E, Miyata T, Inagi R, et al. Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis. J Am Soc Nephrol. 2004;15(6):1574–81.
9. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, et al. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol. 2004;15(5):1277–88.
10. Friederich-Persson M, Thorn E, Hansell P, Nangaku M, Levin M, Palm F. Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension. 2013;62(5):914–9. doi:10.1161/HYPERTENSIONAHA.113.01425.
11. Inoue T, Kozawa E, Okada H, Inukai K, Watanabe S, Kikuta T, et al. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol. 2011;22(8):1429–34. doi:10.1681/ASN.2010111143.
12. Yin WJ, Liu F, Li XM, Yang L, Zhao S, Huang ZX, et al. Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI. Eur J Radiol. 2012;81(7):1426–31. doi:10.1016/j.ejrad.2011.03.045.
13. Bohle A. Change of paradigms in nephrology—a view back and a look forward. Nephrol Dial Transplant. 1998;13(3):556–63.
14. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17–25. doi:10.1681/ASN.2005070757.
15. Welch WJ, Baumgartl H, Lubbers D, Wilcox CS. Nephron pO2 and renal oxygen usage in the hypertensive rat kidney. Kidney Int. 2001;59(1):230–7. doi:10.1046/j.1523-1755.2001.00483.x.
16. Welch WJ, Baumgartl H, Lubbers D, Wilcox CS. Renal oxygenation defects in the spontaneously hypertensive rat: role of AT1 receptors. Kidney Int. 2003;63(1):202–8. doi:10.1046/j.1523-1755.2003.00729.x.
17. Welch WJ, Blau J, Xie H, Chabrashvili T, Wilcox CS. Angiotensin-induced defects in renal oxygenation: role of oxidative stress. Am J Physiol Heart Circ Physiol. 2005;288(1):H22–8. doi:10.1152/ajpheart.00626.2004.
18. Palm F, Nangaku M, Fasching A, Tanaka T, Nordquist L, Hansell P, et al. Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress. Am J Physiol Renal Physiol. 2010;299(2):F380–6. doi:10.1152/ajprenal.00175.2010.
19. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393–402. doi:10.1016/j.molcel.2008.04.009.
20. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5(5):343–54. doi:10.1038/nrm1366.
21. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009;284(25):16767–75. doi:10.1074/jbc.M901790200.
22. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002;295(5556):858–61. doi:10.1126/science.1068592.
23. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, et al. Expression of hypoxia-inducible factor-1α and -2α in hypoxic and ischemic rat kidneys. J Am Soc Nephrol. 2002;13(7):1721–32.
24. Maxwell PH, Ferguson DJ, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, et al. Sites of erythropoietin production. Kidney Int. 1997;51(2):393–401.
25. Yamazaki S, Souma T, Hirano I, Pan X, Minegishi N, Suzuki N, et al. A mouse model of adult-onset anaemia due to erythropoietin deficiency. Nat Commun. 2013;4:1950. doi:10.1038/ncomms2950.
26. Shoji K, Murayama T, Mimura I, Wada T, Kume H, Goto A, et al. Sperm-associated antigen 4, a novel hypoxia-inducible factor 1 target, regulates cytokinesis, and its expression correlates with the prognosis of renal cell carcinoma. Am J Pathol. 2013;182(6):2191–203. doi:10.1016/j.ajpath.2013.02.024.
27. Tanaka T, Yamaguchi J, Shoji K, Nangaku M. Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host. J Biol Chem. 2012;287(42):34866–82. doi:10.1074/jbc.M112.374587.
28. Matsumoto M, Makino Y, Tanaka T, Tanaka H, Ishizaka N, Noiri E, et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol. 2003;14(7):1825–32.
29. Hill P, Shukla D, Tran MG, Aragones J, Cook HT, Carmeliet P, et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2008;19(1):39–46. doi:10.1681/ASN.2006090998.
30. Kojima I, Tanaka T, Inagi R, Kato H, Yamashita T, Sakiyama A, et al. Protective role of hypoxia-inducible factor-2α against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol. 2007;18(4):1218–26. doi:10.1681/ASN.2006060639.
31. Bernhardt WM, Campean V, Kany S, Jurgensen JS, Weidemann A, Warnecke C, et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol. 2006;17(7):1970–8. doi:10.1681/ASN.2005121302.
32. Nangaku M, Rosenberger C, Heyman SN, Eckardt KU. Regulation of hypoxia-inducible factor in kidney disease. Clin Exp Pharmacol Physiol. 2013;40(2):148–57. doi:10.1111/1440-1681.12005.
33. Tanaka T, Kojima I, Ohse T, Inagi R, Miyata T, Ingelfinger JR, et al. Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2005;289(5):F1123–33. doi:10.1152/ajprenal.00081.2005.
34. Weidemann A, Bernhardt WM, Klanke B, Daniel C, Buchholz B, Campean V, et al. HIF activation protects from acute kidney injury. J Am Soc Nephrol. 2008;19(3):486–94. doi:10.1681/ASN.2007040419.
35. Sharples EJ, Thiemermann C, Yaqoob MM. Mechanisms of disease: cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephrol. 2005;1(2):87–97. doi:10.1038/ncpneph0042.
36. Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int. 2006;70(3):432–43. doi:10.1038/sj.ki.5001565.
37. Schley G, Klanke B, Schodel J, Kroning S, Turkoglu G, Beyer A, et al. Selective stabilization of HIF-1α in renal tubular cells by 2-oxoglutarate analogues. Am J Pathol. 2012;181(5):1595–606. doi:10.1016/j.ajpath.2012.07.010.
38. Schley G, Klanke B, Schodel J, Forstreuter F, Shukla D, Kurtz A, et al. Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury. J Am Soc Nephrol. 2011;22(11):2004–15. doi:10.1681/ASN.2010121249.
39. Kapitsinou PP, Sano H, Michael M, Kobayashi H, Davidoff O, Bian A, et al. Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. J Clin Invest. 2014;124(6):2396–409. doi:10.1172/JCI69073.
40. Kalucka J, Schley G, Georgescu A, Klanke B, Rossler S, Baumgartl J, et al. Kidney injury is independent of endothelial HIF-1α. J Mol Med (Berl). 2015;93(8):891–904. doi:10.1007/s00109-015-1264-4.
41. Weidemann A, Kalucka A, Schley G, Klanke B, Jantsch J, Olbrich S, et al. HIF-1 in myeloid cells is protective in acute and chronic kidney injury. J Am Soc Nephrol. 2012;23(ASN abstract):481A.
42. Kolyada AY, Tighiouart H, Perianayagam MC, Liangos O, Madias NE, Jaber BL. A genetic variant of hypoxia-inducible factor-1α is associated with adverse outcomes in acute kidney injury. Kidney Int. 2009;75(12):1322–9. doi:10.1038/ki.2009.68.
43. Rudnicki M, Perco P, Enrich J, Eder S, Heininger D, Bernthaler A, et al. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest. 2009;89(3):337–46. doi:10.1038/labinvest.2008.158.
44. Tanaka T, Miyata T, Inagi R, Fujita T, Nangaku M. Hypoxia in renal disease with proteinuria and/or glomerular hypertension. Am J Pathol. 2004;165(6):1979–92. doi:10.1016/S0002-9440(10)63249-X.
45. Rosenberger C, Khamaisi M, Abassi Z, Shilo V, Weksler-Zangen S, Goldfarb M, et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int. 2008;73(1):34–42. doi:10.1038/sj.ki.5002567.
46. Katavetin P, Miyata T, Inagi R, Tanaka T, Sassa R, Ingelfinger JR, et al. High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol. 2006;17(5):1405–13. doi:10.1681/ASN.2005090918.
47. Zhu XY, Chade AR, Rodriguez-Porcel M, Bentley MD, Ritman EL, Lerman A, et al. Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24(10):1854–9. doi:10.1161/01.ATV.0000142443.52606.81.
48. Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, Brownlee M, et al. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem. 2008;283(16):10930–8. doi:10.1074/jbc.M707451200.
49. Chiang CK, Tanaka T, Inagi R, Fujita T, Nangaku M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest. 2011;91(11):1564–71. doi:10.1038/labinvest.2011.114.
50. Tanaka T, Yamaguchi J, Higashijima Y, Nangaku M. Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia. FASEB J. 2013;27(10):4059–75. doi:10.1096/fj.13-231837.
51. Yamanaka S, Yokote S, Yamada A, Katsuoka Y, Izuhara L, Shimada Y, et al. Adipose tissue-derived mesenchymal stem cells in long-term dialysis patients display downregulation of PCAF expression and poor angiogenesis activation. PLoS One. 2014;9(7):e102311. doi:10.1371/journal.pone.0102311.
52. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature. 2008;453(7196):807–11. doi:10.1038/nature06905.
53. Yamaguchi J, Tanaka T, Eto N, Nangaku M. Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein delta. Kidney Int. 2015;88(2):262–75. doi:10.1038/ki.2015.21.
54. Tanaka T, Matsumoto M, Inagi R, Miyata T, Kojima I, Ohse T, et al. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int. 2005;68(6):2714–25. doi:10.1111/j.1523-1755.2005.00742.x.
55. Tanaka T, Kojima I, Ohse T, Ingelfinger JR, Adler S, Fujita T, et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest. 2005;85(10):1292–307. doi:10.1038/labinvest.3700328.
56. Song YR, You SJ, Lee YM, Chin HJ, Chae DW, Oh YK, et al. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant. 2010;25(1):77–85. doi:10.1093/ndt/gfp454.
57. Yu X, Fang Y, Ding X, Liu H, Zhu J, Zou J, et al. Transient hypoxia-inducible factor activation in rat renal ablation and reduced fibrosis with l-mimosine. Nephrol (Carlton). 2012;17(1):58–67. doi:10.1111/j.1440-1797.2011.01498.x.
58. Nordquist L, Friederich-Persson M, Fasching A, Liss P, Shoji K, Nangaku M, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J Am Soc Nephrol. 2015;26(2):328–38. doi:10.1681/ASN.2013090990.
59. Kobayashi H, Gilbert V, Liu Q, Kapitsinou PP, Unger TL, Rha J, et al. Myeloid cell-derived hypoxia-inducible factor attenuates inflammation in unilateral ureteral obstruction-induced kidney injury. J Immunol. 2012;188(10):5106–15. doi:10.4049/jimmunol.1103377.
60. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007;117(12):3810–20. doi:10.1172/JCI30487.
61. LeBleu VS, Taduri G, O’Connell J, Teng Y, Cooke VG, Woda C, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013;19(8):1047–53. doi:10.1038/nm.3218.
62. Inoue T, Umezawa A, Takenaka T, Suzuki H, Okada H. The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models. Kidney Int. 2015;87(1):233–8. doi:10.1038/ki.2014.235.
63. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010;176(1):85–97. doi:10.2353/ajpath.2010.090517.
64. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest. 2011;121(2):468–74.
65. Kimura K, Iwano M, Higgins DF, Yamaguchi Y, Nakatani K, Harada K, et al. Stable expression of HIF-1α in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol. 2008;295(4):F1023–9. doi:10.1152/ajprenal.90209.2008.
66. Schietke RE, Hackenbeck T, Tran M, Gunther R, Klanke B, Warnecke CL, et al. Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts. PLoS One. 2012;7(1):e31034. doi:10.1371/journal.pone.0031034.
67. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL. Nature. 2003;425(6955):307–11. doi:10.1038/nature01874.
68. Ding M, Cui S, Li C, Jothy S, Haase V, Steer BM, et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med. 2006;12(9):1081–7. doi:10.1038/nm1460.
69. Safran M, Kim WY, O’Connell F, Flippin L, Gunzler V, Horner JW, et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci. 2006;103(1):105–10. doi:10.1073/pnas.0509459103.
70. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG Jr. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol. 2009;29(21):5729–41. doi:10.1128/MCB.00331-09.
71. Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007;117(6):1616–26. doi:10.1172/JCI31581.
72. Regan JN, Lim J, Shi Y, Joeng KS, Arbeit JM, Shohet RV, et al. Up-regulation of glycolytic metabolism is required for HIF1α-driven bone formation. Proc Natl Acad Sci. 2014;111(23):8673–8. doi:10.1073/pnas.1324290111.
73. Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Gunzler V, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12):2151–6. doi:10.1681/ASN.2010010116.
74. Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–73. doi:10.1093/ndt/gfv302.
75. Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2015;. doi:10.1681/ASN.2015030241.
76. Bernhardt WM, Gottmann U, Doyon F, Buchholz B, Campean V, Schodel J, et al. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci. 2009;106(50):21276–81. doi:10.1073/pnas.0903978106.
77. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 2002;1(3):247–55.
78. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel–Lindau protein. Cancer Cell. 2002;1(3):237–46.
79. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003;1(3):E83. doi:10.1371/journal.pbio.0000083.
80. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. Generation of a mouse model of Von Hippel–Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Res. 2011;71(21):6848–56. doi:10.1158/0008-5472.CAN-11-1745.